Home
overview

For the latest COVID-19 Travel restrictions and recommendations please click here

SMi’s 6th Annual Conference
Highly Potent Active Pharmaceutical Ingredients
9 - 10 May, 2022 | London, UK
-------------------------------------------------------------------------
 

The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. The conference will encompass the critical topics including risk assessment, occupational toxicology, engineering controls for containment, facility design, and the impact of pharmaceutical manufacture on the environment.

To register your interest or to get involved please contact: eshambler@smi-online.co.uk

 

This two-day agenda offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies.
 

 

  • Dissect comprehensive hazard assessment and occupational exposure limit determination
  • Evaluate the increasing trend toward more potent therapies and the consequences of the changing face of pharma
  • Assess engineering containment controls, from isolators and barriers to fully automated lines
  • Explore the employment of cleaning validation, organisational controls, and facility as key measure to tackle cross contamination

     

 

Key job titles include:

Head of Occupational hygiene
Head of Industrial hygiene
Head of Containment
Head of Corporate Toxicology
Head of Validation
Director of Operation Quality
Director of EHS
Director of Drug Safety Evaluation
Industrial Engineer
Validation Expert
Manufacturing Specialist
QA Specialist/Manager
Scale-up Operations Manager
 

AbbVie; AstraZeneca; Bayer AG, R&D, Pharmaceutical; Boehringer Ingelheim; Boehringer Ingelheim GmbH; Boehringer Ingelheim GmbH & Co. KG; Bristol Myers Squibb; Bristol-Myers Squibb; Catalent Pharma Solutions; Colorcon; F. Hoffmann-La Roche Ltd.; F.P.S. Food and Pharma Systems Srl; Ferring Controlled Therapeutics ; Formerly of Boehringer Ingelheim Pharmaceuticals; FPS America LLC; Genentech; GSK; HPAPI Project Services Limited; IES Engineers; Novartis; Novartis Pharmaceuticals; Novo Nordisk; Pharmadagio Limited; Regeneron Pharmaceuticals; SKAN AG; Takeda; Takeda (Shire); Takeda Pharmaceutical Company Limited; Takeda Pharmaceuticals; Takeda Pharmaceuticals Company Limited; Vanessa Research; ZF Polpharma SA;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Justin Mason-Home

Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
View Bio

9:10 Key Elements of [Highly] Potent API Projects

Justin Mason-Home

Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
View Bio

• What is more Important? Product Safety or Worker Safety?
• Higher Potency and Toxicity in Drug Pipelines
• Is SARS-CoV-2 and/or its Vaccines ‘Potent’?
• Hazard, Risk and Control (and uncertainty)
• Potent Drug Facility Design
 

9:50 Guidance for establishing Health-Based Exposure Limits (HBELs)

Martin Kohan

Martin Kohan, Senior Occupational Toxicologist, AstraZeneca
View Bio

• Demonstrating the need for a qualified expert to establish HBELs
• Differences between an identified hazard and a perceived risk
• Compounds with limited data - Occupational Exposure Bands as initial guidance
 

10:30 Morning Coffee

11:00 The Journey to Respirator-Free Potent Compound Handling in the QC Laboratory

Toral Mehta

Toral Mehta, SME, Industrial Hygiene, Global EHS, MSD Animal Health
View Bio

• HPAPI: Hazard and Risk Assessment for QC Lab
• Technical Containment: Implementation and Verification
• Challenges and Solutions for Laboratory Containment
• Ultimate success – Respirator-Free QC Laboratory
 

11:40 Human behaviours leading to safe & successful potent product manufacturing

Damien Boyd

Damien Boyd, EHS Specialist Occupational Hygiene, GlaxoSmithKline
View Bio

• There have been progressive improvements in potent compound containment in Pharma within the last 20 years
• Great sharing of ‘best practice’, resulting in similar approaches across the sector,
• A degree of ‘health & safety anxiety’ is observed when the API OELs go below 10 mcg/m3
• Expensive Containment infrastructure is only as useful as the human capability interacting with it
• Do we need to look at how we prepare workers handling extremely active, harmful chemical agents?
• This talk examines some of the key human factors that can influence a successful approach to handling potent compounds
 

12:20 Networking Lunch

13:20 Engaging in proper risk assessment for contract manufacturing of highly potent APIs

Anna Kulesza

Anna Kulesza, Director Pharmaceutical Development, Clovis Oncology
View Bio

• Assessing safety profile of drug substances for quality risk management programs
• The business case for containment: improvements in drug quality and yield, and productivity
• Applying cross-benefit analysis to showcase the ROI gained from effective risk mitigation
 

14:00 Hazards and Potency of new therapeutic modalities

Ester Lovsin Barle

Ester Lovsin Barle, Head of Product Stewardship and Health , Takeda Pharmaceutical Company Limited
View Bio

• Assessment of data relevancy, adequacy, reliability
• Determination of exposure limits in the absence of data
• Case study of nucleic acids
 

14:40 Afternoon Tea

15:10 Legal aspects on handling highly potent active pharmaceutical ingredients and the need to combine GMP and EHS considerations

Reinhold Maeck

Reinhold Maeck, Head of Corporation EH&S Regulatory Intelligence, Boehringer Ingelheim
View Bio

• Bullet points to be confirmed

15:50 How to handle HPAPIs within Chemical Development (case studies)

Thomas Adam

Thomas Adam, QA-Manager, Bayer AG, R&D, Pharmaceutical
View Bio

• GMP-Compliance and Regulatory Environment
• Cleaning of Equipment in the Manufacturing of HPAPIs
• Prevention of Cross-Contamination in Shared Facilities
 

16:30 Chair’s Closing Remarks and Close of Day One

Justin Mason-Home

Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
View Bio

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Justin Mason-Home

Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
View Bio

9:10 Trends and Outlook on Containment

Richard Denk

Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
View Bio

• What are the current and future trends in Containment
• Fully automated Gloveless Robotic Aseptic Filling Line for high potent substances
• Clean to prevent Cross Contamination
• New ISPE DACH Containment Handbook introduction
 

9:50 PANEL DISCUSSION: Highly Potent APIs in Pharma

• How can we ensure compliance with both Good Manufacturing Practice (GMP) and Environmental Health and Safety (EHS)? 
         o Could there be a conflict, and how would we solve it then?
         o Is there a business case for containment controls?
• When should engineering controls be employed?
         o Is establishing human behavioural controls more important than using PPE?
• How should Risk, Hazard, and Uncertainty be treated in this field?
 

Justin Mason-Home

Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
View Bio

Damien Boyd

Damien Boyd, EHS Specialist Occupational Hygiene, GlaxoSmithKline
View Bio

Richard Denk

Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
View Bio

Olindo Lazzaro

Olindo Lazzaro, Head, Global Occupational Safety, Novartis
View Bio

10:30 Morning Coffee

11:00 HSE Risks Mitigation Measures in Novartis AAA radioligand Supply Chain

• Drugs for targeted radioligand therapy
• AAA technology platform
• HSE Hazards of radioligands
• Manufacturing Process and Supply Chain: HSE Aspects
• HSE Risks Mitigation Strategy
 

Olindo Lazzaro

Olindo Lazzaro, Head, Global Occupational Safety, Novartis
View Bio

Christophe Dehondt

Christophe Dehondt, Global Head of EHS and BCM, Novartis, Advanced Accelerator Applications

11:40 Antibody-Drug Conjugates (ADCs) – antibodies meeting HPAPIs for specific and efficient bio-pharmaceutical drugs

Ulrich Rumenapp

Ulrich Rumenapp, Head of Launch Preparation and Coordination, Bayer AG

• The manufacture of ADCs - challenges and solutions
• The make-or-buy question - deciding to manufacture in-house or outsource
• Bayer’s ADC production concept using HPAPIs
• Best practices for CDMO selection and outsourcing ADC development and manufacturing
• Understanding the success factors, risks and mitigations in externalisation of ADCs
 

12:20 Networking Lunch

13:20 Policy measures at the EU level on pharmaceuticals in the environment

Adela Maghear

Adela Maghear, President, Institut Vert
View Bio

• In March 2019, the Commission adopted the long-awaited strategic approach to pharmaceuticals in the environment, as required by Article 8c of Directive 2008/105/EC as amended by Directive 2013/39/EU
• The approach covers all stages of the lifecycle of pharmaceuticals, from design and production through use to disposal
• While progress has been made in implementing the actions of the EU Strategic Approach to Pharmaceuticals in the Environment, several Green Deal Initiatives and the EU Pharmaceutical Strategy are aimed to pave the way towards making the EU the first region to legislate on pharmaceuticals in the environment
 

14:00 Establishing the business case for containment

David Eherts

David Eherts, Principal Consultant, National Safety Council - ORCHSE (Eherts Consulting LLC)
View Bio

• Designing a risk-informed hazard management procedure with accurate health-based exposure limits
• Showcasing a cross benefit analysis to translate containment strategy into deployed isolator technology
• Demonstrating how closed-systems protect product yield and quality
• Exemplifying how recuing PPE improves operator efficiency and workforce productivity
 

14:40 Afternoon Tea

15:10 Performance Beyond ‘The Number’ – Exploring the Reliability of Containment Performance Data

15:50 Adaptation of containment designs to cope with the high demands of HPAPIs

16:30 Chairman’s Closing Remarks and Close of Day Two

+

FEATURED SPEAKERS

Adela Maghear

Adela Maghear

President, Institut Vert
Anna Kulesza

Anna Kulesza

Director Pharmaceutical Development, Clovis Oncology
Damien Boyd

Damien Boyd

EHS Specialist Occupational Hygiene, GlaxoSmithKline
David Eherts

David Eherts

Principal Consultant, National Safety Council - ORCHSE (Eherts Consulting LLC)
Ester Lovsin Barle

Ester Lovsin Barle

Head of Product Stewardship and Health , Takeda Pharmaceutical Company Limited
Justin Mason-Home

Justin Mason-Home

Owner, Director, HPAPI Project Services Limited
Martin Kohan

Martin Kohan

Senior Occupational Toxicologist, AstraZeneca
Olindo Lazzaro

Olindo Lazzaro

Head, Global Occupational Safety, Novartis
Reinhold Maeck

Reinhold Maeck

Head of Corporation EH&S Regulatory Intelligence, Boehringer Ingelheim
Richard Denk

Richard Denk

Senior Consultant Aseptic Processing & Containment, SKAN AG
Thomas Adam

Thomas Adam

QA-Manager, Bayer AG, R&D, Pharmaceutical
Toral Mehta

Toral Mehta

SME, Industrial Hygiene, Global EHS, MSD Animal Health
Ulrich Rumenapp

Ulrich Rumenapp

Head of Launch Preparation and Coordination, Bayer AG

Adela Maghear

President, Institut Vert
Adela Maghear

Adela is a graduate in pharmacy studies and holds two PhD degrees; one in Medical Sciences (Field of Pharmacy) and another in Chemistry awarded by the University of Medicine and Pharmacy Cluj-Napoca (Romania) and University of Lorraine (France), respectively.

With a strong focus on environmental safety, her research work and scientific publications have dealt with a wide range of subjects. In 2015, she changed career paths when she received the Robert Schuman scholarship at the European Parliament Research Service in Brussels. Her career within the field of health policies continued as she became a member of the European Health Parliament, Antimicrobial Resistance Committee, that same year.

In 2016, she ushered her skills and expertise in the fields of health and environment to ‘Health Care Without Harm Europe’ where she spearheaded the organisation’s policy work related to pharmaceuticals in the environment and antimicrobial resistance. She developed and led the Safer Pharma Campaign, aimed to make the EU the first region in the world to legislate on pharmaceutical pollution and its consequent contribution to the spread of AMR.

Her work has been cited in international journals such as The Telegraph, ChemicalWatch UK, Pharmaceutical Technology, Market Business News, Pharma Technology Focus and Health Europa.

In 2020, she co-founded “Institut Vert” – a non-profit association that aims to foster greater involvement by citizens in South-Eastern countries in European politics to ensure a common green and sustainable vision that could benefit all.

 

Anna Kulesza

Director Pharmaceutical Development, Clovis Oncology
Anna Kulesza

Currently Director CMC Pharmaceutical development at Clovis Oncology Switzerland GmbH Responsible for definition and management of contractor activities related to development and manufacturing of drug substances and/or drug products, and development and validation of analytical methods. The scope of work will support products at all stages of development up to and including commercialization. Past experience includes program management and innovation management in contract manufacturing at Lonza AG for drug substance development, validation and manufacturing for clinical phases and commercialization.

Christophe Dehondt

Global Head of EHS and BCM, Novartis, Advanced Accelerator Applications
Christophe Dehondt

Damien Boyd

EHS Specialist Occupational Hygiene, GlaxoSmithKline
Damien Boyd

Dr. Damien Boyd is an Analytical Chemist who changed career to re-train as an Occupational Hygienist. He completed the British Occupational Hygiene Society (BOHS) programme to become a Chartered member (‘the CMFOH’ level). He was winner of the annual David Hickish award, presented by the Society, in 2012.
He is presently working in the Pharma sector in a regional, advising role. He also teaches Occupational Hygiene, Chemistry and Toxicology, part time, at University College Cork, Ireland.
He has been an advisor of safe work practice with handling potent compounds over a 22-year period.
He is particularly interested in the specific human mind-set, required by employees, to work in the more rigid and specialised field of potent compound manufacture.
 

David Eherts

Principal Consultant, National Safety Council - ORCHSE (Eherts Consulting LLC)
David Eherts

Dr. Eherts retired from Allergan Pharmaceuticals at the end of 2020 and is currently consulting for NSC-ORCHSE and teaching at Tulane University’s School of Public Health.
David has enjoyed 40-year career in the fields of Safety Assessment, EHS, Sustainability and Employee Health starting as a toxicologist in Pre-Clinical Drug Safety Assessment at Merck. He moved to EHS and has held positions of increasing responsibility in the pharmaceutical, healthcare and aviation industries most recently at Allergan as their Global Vice President for EHS and immediately prior to that at Sikorsky Aircraft as the Vice President and Chief Safety Officer leading their EHS, Aviation and Product Safety, Medical and Government Security functions.
Dave holds Bachelor’s degrees in Chemistry and Biology and a Masters and PhD in Environmental Toxicology from Drexel University.
Related to professional societies, organizations and awards, David was recently honored by NAEM (the National Association of EHS Management) with their Lifetime Achievement Award in 2019 and as the National Safety Council (ORCHSE) Innovation Award Winner in 2018. Under the Obama administration, David was appointed by the US Secretary of Labor to serve on the Federal Whistleblower Protection Advisory Committee (heading the 11c Subcommittee) from 2014-2018. He’s chaired the ISPE Containment CoP (2016-2020), served on the Board of Directors of Occupational Knowledge International, on the Board and chaired the Environmental Business Committee at SoundWaters and on the advisory board for the ORC Executive Business Issues Forum where he led the Return-on-HSE-Investment (ROHSEI) Taskforce.
 

Ester Lovsin Barle

Head of Product Stewardship and Health , Takeda Pharmaceutical Company Limited
Ester Lovsin Barle

Ester Lovsin Barle, DVM, MSc, PhD, MScTox is the Head of Product Stewardship and Health at Takeda. She lives in Zurich, Switzerland.
Her responsibilities include Safety Data Sheet process, maintaining article and material regulatory compliance and scientific development and cross-organizational implementation of health based exposure limits (HBEL) in support of research and manufacturing in Takeda globally, global implementation of occupational hygiene and product stewardship sustainability activities. Previously she has held corporate positions at Lonza and Novartis. She received her PhD in veterinary sciences from University of Ljubljana, Slovenia and a second masters degree in toxicology and risk assessment from Medical University in Vienna.
 

Justin Mason-Home

Owner, Director, HPAPI Project Services Limited
Justin Mason-Home

Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the biopharmaceutical, industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety global environmental consulting, board level positions in a biotechnology company and corporate environmental management. Mr Mason-Home specialises in technical complex and strategic projects, including unique experience in managing sensitive highly potent and toxic biopharmaceutical compound matters.

Martin Kohan

Senior Occupational Toxicologist, AstraZeneca
Martin Kohan

Martin Kohan PhD, ERT, DABT
Position: Senior Occupational Toxicologist, AstraZeneca UK.

BSc/MSc in Biochemistry from La Plata National University, Argentina; MSc in Pharmacology and PhD in Medical Sciences both from the Hebrew University of Jerusalem, Israel. Over 10 years of industry experience in the field of Toxicology conducting and managing over 1000 hazard and risk assessments, including calculation of exposure limits and/or determination of exposure control bands for drug substances and isolated intermediates and quality deviations (impurities and extractables & leachables) for Teva (2010 to 2018) and AstraZeneca (2018 to present). Diplomate of the American Board of Toxicology (DABT), European Registered Toxicologist (ERT), and Member of the UK Register of Toxicologists and of the British Toxicology Society.
 

Olindo Lazzaro

Head, Global Occupational Safety, Novartis
Olindo Lazzaro

Olindo Lazzaro, is Director Global EHS Technical Operations at AbbVie, responsible for EHS Technical Centers of Excellence supporting both R&D and Manufacturing at Global Level. His key areas of focus are: Process Safety Management, Loss Prevention and Fire Protection, Serious Injury and Fatality (SIF) Prevention, OH/Containment, Pharmaceuticals In the Environment (PiE), Environmental Best Available Techniques (BAT)/Ecoefficiency, EHS Technical Transfer Process, Positive Safety Culture, EHS Management Systems (ISO 14001, ISO 45001, EMAS) and EHS Audit, EHS Business Integration and EHS Performance Improvement.

Previously he has been the Director, EHS, Global Manufacturing & TPMs at Abbott then AbbVie, with Direct accountability for Environment, Health, Safety & Energy (EHS&E) performance and compliance throughout AbbVie’s manufacturing sites and TPMs Globally.
Olindo has 25 years of experience in EHS and Pharmaceutical & Chemical Operations, including international experience in EHS management, Technical Transfer, network optimization and post M&A EHS integration.

 

Reinhold Maeck

Head of Corporation EH&S Regulatory Intelligence, Boehringer Ingelheim
Reinhold Maeck

Large international experience by living for several years in China, US, and several European countries as well as by auditing and interacting with the production network and suppliers of Boehringer Ingelheim.
Extensive experience in Corporate Headquarters as well as in direct operational responsibility of large chemical plants.
Co-Author of the Containment Handbook -actual working on a new revised version and steering committee member at ISPE DACH Containment and representing BI from an EHS perspective at various organisations and associations such as (AMR Alliance, EFPIA…)
Head of Corporate EHS&S Regulatory Intelligence 2014-actual
Boehringer Ingelheim Corporate Center GmbH, Ingelheim Germany)
Understandings of regulations and upcoming regulations worldwide in the field of environmental and safety topics with a strong impact on the business of BI. This does include regulations relevant for sustainability and for the integrity of the supply chain. Representing BI in associations and/ or briefing of top management for all EHS topics in such associations. In this corporate function closely linked to the managements as well as to the Corporate Public Affairs. In addition, lead auditor for critical supply chain topics.
 

Richard Denk

Senior Consultant Aseptic Processing & Containment, SKAN AG
Richard Denk

Richard Denk is working at the company SKAN AG, headquartered in Allschwil Switzerland in the position Senior Consultant Aseptic Processing & Containment. Richard is member of the PDA Isolator Expert Group, ISPE Sterile Product Processing Group, Chair of the ISPE Containment DACH, Chair of the ISPE DACH Containment Manual and Richard developed the Containment Pyramid. Richard is co-founder and chair of the ISPE SIG Future Robotic and Co-Chair ISPE SIG Bio on Innovations and Technology. Furthermore, Richard is Member of the ISO TC 198 WG-9 Aseptic Isolator Group.

Thomas Adam

QA-Manager, Bayer AG, R&D, Pharmaceutical
Thomas Adam

Dr. Thomas Adam is currently the head of global quality assurance chemical APIs in the chemical development department of the pharmaceutical business unit of Bayer.
He is responsible for the release of chemical APIs for clinical trials, the GMP-Quality system and
the QA-oversight of the pilot plants and analytical development laboratories.

Thomas holds a PhD in analytical chemistry from the University of Mainz in Germany.
He has about 20 years of industrial experience at Bayer AG in different QC/QA-functions and a two years Post-Doc experience at Novartis, Switzerland.
He is and was involved in many technical (transfer)-projects so as the planning and launching of the new GMP-kg lab for highly potent APIs and establishing a cleaning concept for the chemical development department.
 

Toral Mehta

SME, Industrial Hygiene, Global EHS, MSD Animal Health
Toral Mehta

In her 22+ years of global EHS professional career, Toral lived and worked in 3 continents and worked in @ 40+ countries. From beginning of her career, Toral worked closely with multinational pharmaceuticals. Since last 7.5 years she has been part of Global EHS Team in multinational Pharma - Novartis and now at MSD/Merck. Currently she is in Vienna, Austria working at a high potent API (HPAPI) facility focused on establishing robust IH program and major capital investment projects related to Industrial Hygiene and Containment.
 

Ulrich Rumenapp

Head of Launch Preparation and Coordination, Bayer AG
Ulrich Rumenapp

Ulrich Rumenapp

Head of Launch Preparation, Bayer AG
Ulrich Rumenapp

Supporters

Workshops

Making the Business Case for Capital Investment in Containment
Workshop

Making the Business Case for Capital Investment in Containment

Copthorne Tara Hotel
11th May 2022
London, United Kingdom

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

HPAPi 2022 Brochure

Download

Media Partners


Mednous

Supporters
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Pharmiweb

Supporters
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


Samedan

Supporters
http://www.samedanltd.com/magazine/13.

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


American Pharmaceutical Review

Supporters
http://www.americanpharmaceuticalreview.com

Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


Technology Networks

Supporters
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Speciality Chemicals Online

Supporters
https://www.specchemonline.com/

Published continuously since 1981, Speciality Chemicals Magazine is the leading monthly magazine dedicated to covering business, markets and technology in the fine and speciality chemicals industries world-wide. We have over 50,000 readers and a calendar of features covering the full gamut of applications, including pharmaceuticals, agrochemicals, cosmetics and personal care, biobased chemicals, surfactants, biocides and much more.


ASD MEDIA

Supporters
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


pharmaphorum

Supporters
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


IPI

Supporters
http://international-pharma.com/

International Pharmaceutical Industry is a peer-reviewed journal. We are committed to editorial integrity. Supported by an elite group of reviewers and industry experts, IPI brings you contemporary and authoritative articles which will guide the industry in the best practice in regulatory issues, market analysis, drug discovery, development, delivery methods, clinical research, laboratories, analytical testing, custom and contract manufacturing, primary and secondary packaging, logistics and supply chain management.


pharmanews hq

Supporters
http://http://pharmanewshq.com

MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out